NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice rapidly changed after the introduction of effective molecularly targeted therapy (such as imatinib and sunitinib) for GIST. Because of these changes, NCCN organized a multidisciplinary panel composed of experts in the fields of medical oncology, molecular diagnostics, pathology, radiation oncology, and surgery to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST Task Force is composed of NCCN faculty and other key experts from the United States, Europe, and Australia. The Task Force met for the first time in October 2003 and again in December 2006 with the purpose of expanding on the existing NCCN guidelines for gastrointestinal sarcomas and identifying areas of future research to optimize our understanding and treatment of GIST.
Demetri
George D
GD
Benjamin
Robert S
RS
Blanke
Charles D
CD
Blay
Jean-Yves
JY
Casali
Paolo
P
Choi
Haesun
H
Corless
Christopher L
CL
Debiec-Rychter
Maria
M
DeMatteo
Ronald P
RP
Ettinger
David S
DS
Fisher
George A
GA
Fletcher
Christopher D M
CD
Gronchi
Alessandro
A
Hohenberger
Peter
P
Hughes
Miranda
M
Joensuu
Heikki
H
Judson
Ian
I
Le Cesne
Axel
A
Maki
Robert G
RG
Morse
Michael
M
Pappo
Alberto S
AS
Pisters
Peter W T
PW
Raut
Chandrajit P
CP
Reichardt
Peter
P
Tyler
Douglas S
DS
Van den Abbeele
Annick D
AD
von Mehren
Margaret
M
Wayne
Jeffrey D
JD
Zalcberg
John
J
D026683:Advisory Committees; D001549:Benzamides; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D014481:United States / Q000453:epidemiology
D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D000077210:Sunitinib